Skip to main content

RXi Begins Phase I Trial of Anti-Scarring Drug Candidate


RXi Pharmaceuticals said this week that it has begun a phase I trial of its anti-scarring compound RXI-109, marking the start of the company's first ever clinical trial.

RXI-109 uses the company's so-called self-delivering RNAi technology to inhibit connective tissue growth factor, a protein linked to wound healing and other fibrotic processes. The phase I study is examining the compound in surgical patients.

Since it was spun out of CytRx in 2007, RXi has on several occasions failed to meet publicly stated guidance on the start of clinical studies for its various drug candidates. Recently appointed CEO Geert Cauwenbergh, however, told Gene Silencing News last month that he had made the RXI-109 phase I trial a priority (GSN 5/17/2012).

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.